Advocacy groups criticize pricing of hepatitis C drug
BY Advocate.com Editors
November 12 2002 1:00 AM ET
AIDS and hepatitis advocacy groups last week sent a letter to drugmaker Hoffmann-LaRoche criticizing the company for the high cost of its new hepatitis C medication Pegasys, the Newark Star-Ledger reports. The drug, approved by the Food and Drug Administration in October, will cost more than $14,000 per year. The groups, including Project Inform, the Hepatitis C Action and Advocacy Coalition, the AIDS Treatment Data Network, and the Treatment Action Group, threatened to draw congressional and media attention to the pricing of the medication if the company does not voluntarily reduce the price of Pegasys. Hoffmann-LaRoche spokesperson Charles Alfaro said that the company has not yet received the letter and therefore could not comment on its contents. He added that Pegasys is "priced competitively."
- Gay Artists & Artwork From Around the Globe | Artist Spotlight
- California Becomes First State to Ban Gay, Trans 'Panic' Defenses
- Read This Mich. Democrat's Epic Response to Antigay Group's 'Pile of Excrement'
- The New 'Republicans Are People Too' Twitter Campaign Is An Epic Fail
- 10 Transgender Kings and Queens Who Ruled the School
- GLAAD Issues Record Number of 'Excellent' Ratings for TV Networks